NCT03739554View on ClinicalTrials.gov

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 25, 2019

Primary Completion Date

November 15, 2022

Study Completion Date

April 27, 2023

Conditions
Relapsed or Refractory Chronic Lymphocytic Leukemia
Interventions
DRUG

CYC065

intravenous infusion

DRUG

Venetoclax

oral capsule

Trial Locations (3)

21201

Investigational Site, Baltimore

28204

Investigational Site, Charlotte

77030

Investigational Site, Houston

Sponsors
All Listed Sponsors
lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT03739554 - CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL | Biotech Hunter | Biotech Hunter